"At the Cancer Partnership, we know that when you hear the words, “You have cancer,” it’s easy to feel overwhelmed. You no doubt wonder what it means for you and your family, and soon may find yourself asking, “So, what do I do now?” Everyone’s cancer journey is unique. Our cancer specialists try to learn as much as we can about you and your cancer to develop a treatment plan that’s just right for you. Generally, at the Cancer Partnership, you’ll meet with a doctor who is an expert in the type of cancer you have very soon after your diagnosis. The doctor will find out what’s important to you and outline your treatment options to help you make an informed decision about how to proceed."

During the past decade, Providence Regional Cancer Partnership conducted 170 clinical trials. In the 10-year time frame, 170 clinical trials started and 102 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 73 clinical trials started and 73 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Providence Regional Cancer Partnership" #1 sponsor was "National Cancer Institute (NCI)" with 99 trials, followed by "SWOG Cancer Research Network" with 40 trials sponsored, "Alliance for Clinical Trials in Oncology" with 38 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 17 trials sponsored and "Hoffmann-La Roche" with 17 trials sponsored. Other sponsors include 38 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Providence Regional Cancer Partnership" #1 collaborator was "National Cancer Institute (NCI)" with 114 trials as a collaborator, "NRG Oncology" with 25 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator and "Millennium Pharmaceuticals, Inc." with 3 trials as a collaborator. Other collaborators include 26 different institutions and companies that were collaborators in the rest 33 trials.

According to Clinical.Site data, the most researched conditions in "Providence Regional Cancer Partnership" are "Breast Cancer" (10 trials), "Recurrent Ovarian Carcinoma" (10 trials), "Recurrent Squamous Cell Lung Carcinoma" (10 trials), "Lung Cancer" (8 trials) and "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials). Many other conditions were trialed in "Providence Regional Cancer Partnership" in a lesser frequency.

Most popular intervention types in "Providence Regional Cancer Partnership" are "Drug" (203 trials), "Other" (129 trials), "Biological" (96 trials), "Procedure" (55 trials) and "Radiation" (27 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (62 trials), "Quality-of-Life Assessment" (50 trials), "Paclitaxel" (35 trials), "Computed Tomography" (31 trials) and "Carboplatin" (30 trials). Other intervention names were less common.

The vast majority of trials in "Providence Regional Cancer Partnership" are 191 trials for "All" genders, 46 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are NaN active trials in "Providence Regional Cancer Partnership". undefined are not yet recruiting, 65 are recruiting, 104 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 52 completed trials in Providence Regional Cancer Partnership, 5 suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in Providence Regional Cancer Partnership, 6 "Phase 1" clinical trials were conducted, 113 "Phase 2" clinical trials and 129 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 4 trials that are defined as “Not Applicable".